IFITM3 and acute myeloid leukemia: IFNγ is one of the main mediators of inflammation in cancer and development of an IFNγ signaling score led to the identification of IFITM3 as both a prognostic biomarker and a direct target of IFNγ with a potential dependency in AML cells lines, i.e., its deletion led to loss of AML cell fitness.